Europe Menstrual Cramps Treatment Market
Market Size in USD Billion
CAGR :
% 
USD
1.48 Billion
USD
2.55 Billion
2024
2032
 Forecast Period |
2025 –2032 |
 Market Size (Base Year) |
USD 1.48 Billion |
 Market Size (Forecast Year) |
USD 2.55 Billion |
 CAGR |
% |
| Major Markets Players |
|
European Menstrual Cramps Treatment Market Segmentation, By Type (Primary Dysmenorrhea, Secondary Dysmenorrhea), Treatment Type (Medication, Therapy, Surgery, Others), Mode of Prescription (Over the Counter, Prescription), Route of Administration (Oral, Parenteral, Implants, Others), End User (Hospitals, Specialty Centers, Ambulatory Surgical Centers, Others), Distribution Channel (Pharmacies, Retail Sales, Direct Tender, Others), Country (Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe) Industry Trends and Forecast to 2032
Menstrual Cramps Treatment Market Size
- The European Menstrual Cramps Treatment Market size was valued at USD 1.48 billion in 2024 and is expected to reach USD 2.55 billion by 2032, at a CAGR of 7.10% during the forecast period
- The European menstrual cramps treatment market growth is largely fueled by the increasing prevalence of dysmenorrhea and rising awareness regarding menstrual health, leading to a higher demand for effective treatment options across the region.
- Furthermore, rising consumer demand for safe, efficient, and readily available solutions for menstrual pain relief is establishing various treatment modalities, including over-the-counter medications and advanced non-pharmacological methods, as the modern choice. These converging factors are accelerating the uptake of menstrual cramp treatment solutions, thereby significantly boosting the industry's growth.
Menstrual Cramps Treatment Market Analysis
- Menstrual cramps treatments, offering relief for pain and discomfort associated with menstruation, are increasingly vital components of women's health management due to their enhanced effectiveness, varied administration options, and growing focus on personalized care.
- The escalating demand for menstrual cramps treatments is primarily fueled by the widespread prevalence of dysmenorrhea, rising awareness regarding menstrual health among consumers, and a growing preference for effective and accessible pain relief solutions.
- Europe holds a significant share in the menstrual cramps treatment market, characterized by increased consumption of over-the-counter (OTC) drugs and growing healthcare investments, with countries like Germany and the UK experiencing substantial growth due to increased awareness and a high female population seeking treatment.
- The Asia-Pacific region is expected to be the fastest-growing region in the menstrual cramps treatment market during the forecast period, owing to increasing urbanization, rising disposable incomes, and growing awareness campaigns related to women's health.
- The medication segment, particularly Non-steroidal Anti-inflammatory Drugs (NSAIDs), is expected to dominate the menstrual cramps treatment market, driven by its established reputation for effectiveness, wide availability, and low cost as a first-line therapy for dysmenorrhea.
Report Scope and Menstrual Cramps Treatment Market Segmentation
|
Attributes |
Smart Lock Key Market Insights |
|
Segments Covered |
|
|
Countries Covered |
North America
Europe
Asia-Pacific
Middle East and Africa
South America
|
|
Key Market Players |
|
|
Market Opportunities |
|
|
Value Added Data Infosets |
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, pricing analysis, brand share analysis, consumer survey, demography analysis, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework. |
Menstrual Cramps Treatment Market Trends
“Personalized Pain Management Through AI-Powered Digital Health Solutions”
- A significant and accelerating trend in the European menstrual cramps treatment market is the deepening integration with artificial intelligence (AI) and digital health platforms. This fusion of technologies is significantly enhancing user convenience and control over their pain management strategies.
- For instance, AI-powered period tracking apps like Flo and Clue seamlessly integrate with user-reported symptoms and historical cycle data, allowing them to predict periods, ovulation, and fertile windows with increased accuracy, and often offering personalized insights into managing associated discomfort. Similarly, wearable devices utilizing technologies like TENS (Transcutaneous Electrical Nerve Stimulation) or heat therapy are integrating with smart apps to offer customizable pain relief programs.
- AI integration in menstrual cramps treatment enables features such as learning user pain patterns to potentially suggest optimal treatment timings and providing more intelligent alerts based on symptom severity. For instance, some digital therapeutics utilize AI to improve pain relief recommendations over time and can send intelligent alerts if unusual or severe pain patterns are detected. Furthermore, digital health platforms offer users the ease of tracking symptoms, medication intake, and lifestyle factors, allowing them to better understand and manage their individual menstrual health journey.
- The seamless integration of AI-powered solutions with broader digital health ecosystems facilitates centralized control over various aspects of menstrual well-being. Through a single interface, users can manage their pain relief strategies alongside mood tracking, activity levels, and other health data, creating a unified and automated approach to menstrual health management.
- This trend towards more intelligent, intuitive, and interconnected pain management systems is fundamentally reshaping user expectations for menstrual discomfort relief. Consequently, companies are developing AI-enabled digital health solutions with features such as automatic personalized recommendations for pain relief based on reported symptoms and integrating with other wellness apps.
- The demand for menstrual cramps treatments that offer seamless AI and digital health integration is growing rapidly across the European market, as consumers increasingly prioritize convenience, personalized care, and comprehensive self-management functionalities.
Menstrual Cramps Treatment Market Dynamics
Driver
“Growing Need Due to Rising Prevalence of Dysmenorrhea and Increased Health Awareness”
- The increasing prevalence of menstrual cramps (dysmenorrhea) among women, coupled with the accelerating awareness and open discussion around menstrual health, is a significant driver for the heightened demand for effective menstrual cramps treatments.
- For instance, in recent years, companies have introduced innovative non-pharmacological solutions like wearable heat therapy devices or TENS units, aiming to provide convenient and drug-free pain relief. Such advancements by key companies are expected to drive the menstrual cramps treatment industry growth in the forecast period.
- As individuals become more aware of the impact of menstrual pain on their daily lives and seek enhanced relief and management options, modern treatments offer advanced features such as targeted pain relief, personalized approaches, and reduced side effects, providing a compelling alternative or complement to traditional methods.
- Furthermore, the growing popularity of holistic health approaches and the desire for comprehensive well-being are making menstrual cramps treatments an integral component of these broader health strategies, offering seamless integration with lifestyle modifications and self-care practices.
- The convenience of readily available over-the-counter medications, the accessibility of diverse therapeutic options, and the ability to manage symptoms through user-friendly digital health applications are key factors propelling the adoption of menstrual cramps treatments. The trend towards self-management and the increasing availability of varied treatment options further contribute to market growth.
Restraint/Challenge
“Concerns Regarding Side Effects and Stigma Associated with Treatments”
- Concerns surrounding the potential side effects of pharmaceutical treatments and the societal stigma associated with menstrual health issues pose a significant challenge to broader market penetration. As menstrual cramp treatments often involve medications or therapies, they can be associated with adverse reactions or a reluctance to seek help due to privacy concerns, raising anxieties among potential consumers about the safety and suitability of these options.
- For instance, public awareness of potential side effects from certain medications, or the perceived invasiveness of some therapies, has made some consumers hesitant to adopt conventional treatment solutions.
- Addressing these concerns through robust research, clear communication of benefits versus risks, and the development of more targeted therapies is crucial for building consumer trust. Companies emphasize their rigorous clinical trials and patient support programs to reassure potential buyers. Additionally, the relatively high cost of some advanced or long-term treatment regimens, or insufficient reimbursement policies, can be a barrier to adoption for price-sensitive consumers, particularly for those seeking specialized care. While basic over-the-counter pain relievers are affordable, premium features such as advanced wearable devices or personalized therapy plans often come with a higher price tag.
- While accessibility to various treatments is improving, the perceived burden of continuous management or the preference for non-pharmacological alternatives can still hinder widespread adoption, especially for those seeking more natural or less invasive approaches.
- Overcoming these challenges through enhanced patient education, transparent information on treatment outcomes, and the development of more affordable and accessible therapeutic options will be vital for sustained market growth.
Menstrual Cramps Treatment Market Scope
The market is segmented on the basis of type, treatment type, mode of prescription, route of administration, end user, and distribution channel.
- By Type
On the basis of type, the European menstrual cramps treatment market is segmented into primary dysmenorrhea and secondary dysmenorrhea. The primary dysmenorrhea segment is expected to dominate the market, as the majority of patients experience primary or minor cramp symptoms, and it has a high prevalence across Europe (ranging from 52.4% to 85.7% in various studies). Individuals often prioritize treatments for primary dysmenorrhea due to its widespread occurrence and the availability of accessible relief options. The market also sees strong demand for primary dysmenorrhea treatments due to the increasing awareness of menstrual health and the growing focus on effective pain management.
- The secondary dysmenorrhea segment is anticipated to witness significant growth, driven by the increasing diagnosis of underlying conditions such as endometriosis, uterine fibroids, and adenomyosis. As diagnostic tools and medical understanding improve, more cases of secondary dysmenorrhea are identified, leading to a demand for targeted and often more complex treatment solutions. The rising prevalence of conditions like endometriosis in women across Europe also contributes to the growing need for secondary dysmenorrhea treatments.
By Treatment Type
On the basis of type, the European menstrual cramps treatment market is segmented into primary dysmenorrhea and secondary dysmenorrhea. The primary dysmenorrhea segment is expected to dominate the market, as the majority of patients experience primary or minor cramp symptoms, and it has a high prevalence across Europe (ranging from 52.4% to 85.7% in various studies). Individuals often prioritize treatments for primary dysmenorrhea due to its widespread occurrence and the availability of accessible relief options. The market also sees strong demand for primary dysmenorrhea treatments due to the increasing awareness of menstrual health and the growing focus on effective pain management.
The secondary dysmenorrhea segment is anticipated to witness significant growth, driven by the increasing diagnosis of underlying conditions such as endometriosis, uterine fibroids, and adenomyosis. As diagnostic tools and medical understanding improve, more cases of secondary dysmenorrhea are identified, leading to a demand for targeted and often more complex treatment solutions. The rising prevalence of conditions like endometriosis in women across Europe also contributes to the growing need for secondary dysmenorrhea treatments.
By Mode of Prescription
On the basis of mode of prescription, the European menstrual cramps treatment market is segmented into over-the-counter (OTC) and prescription. The over-the-counter segment is expected to dominate the market, driven by the easy accessibility and affordability of pain relievers like NSAIDs. The increasing trend of self-medication for mild to moderate menstrual pain and growing consumer awareness of readily available solutions contribute significantly to this segment's large share.
The prescription segment is anticipated to witness substantial growth, fueled by the rising diagnosis of severe or secondary dysmenorrhea cases that require stronger medication or hormonal therapies under medical supervision. The increasing number of women seeking professional medical advice for persistent or debilitating menstrual pain, and advancements in targeted prescription treatments, are key factors contributing to the growth of this segment.
By Route of Administration
On the basis of route of administration, the European menstrual cramps treatment market is segmented into oral, parenteral, implants, and others. The oral segment is expected to dominate the market, primarily due to the convenience, familiarity, and widespread availability of oral medications such as pills and capsules. Oral administration remains the most common and preferred method for pain relief due to its ease of use and rapid absorption.
The parenteral and implants segments are anticipated to witness growth, driven by the need for faster pain relief in severe cases (parenteral) or long-term management and hormonal control (implants). These methods offer benefits like sustained release of medication and bypass of the digestive system, making them suitable for specific patient needs or conditions where oral administration is less effective.
Menstrual Cramps Treatment Market Regional Analysis
- Europe is expected to hold a significant market share in the menstrual cramps treatment market, driven by the high prevalence of dysmenorrhea among its female population and advanced healthcare infrastructure. Countries like Germany, France, and the UK are key contributors to this market, showing a strong demand for both over-the-counter and prescription-based treatments.
- Consumers in the region highly value effective pain relief, convenience of access, and a growing acceptance of seeking medical solutions for menstrual discomfort. This is coupled with increasing awareness campaigns and initiatives promoting menstrual health as a vital aspect of overall well-being.
- This widespread adoption is further supported by high healthcare expenditure, a well-informed populace actively engaged in managing their health, and the increasing availability of diverse treatment options, establishing comprehensive menstrual pain management as a favored approach across European countries.
Germany Menstrual Cramps Treatment Market Insight
Germany is a leading market within Europe for menstrual cramps treatment, driven by a high awareness of menstrual health and a robust healthcare system. Consumers in Germany readily access both over-the-counter medications and seek professional medical advice for managing menstrual pain. The market is further propelled by ongoing public health initiatives and the availability of a wide range of pharmaceutical and non-pharmacological treatment options.
France Menstrual Cramps Treatment Market Insight
France holds a significant position in the European menstrual cramps treatment market, fueled by increasing healthcare investments and a growing focus on women's health. There's a rising trend in France towards addressing period poverty and increasing access to menstrual hygiene products, which indirectly supports the broader market for menstrual pain management. The market benefits from both traditional pharmaceutical solutions and an increasing interest in sustainable and alternative pain relief methods
U.K. Menstrual Cramps Treatment Market Insight
The UK market for menstrual cramps treatment is experiencing rapid growth, primarily due to an increasing female population and heightened awareness around menstrual health issues. Consumers in the UK are increasingly seeking effective solutions for menstrual discomfort, leading to a strong demand for both conventional medications and innovative products. Government initiatives aimed at improving access to menstrual products and education further contribute to the market's expansion.
Menstrual Cramps Treatment Market Share
The smart lock industry is primarily led by well-established companies, including:
- Bayer AG (Germany)
- GlaxoSmithKline plc (United Kingdom)
- Pfizer Inc. (USA)
- Teva Pharmaceuticals USA, Inc. (USA)
- Color Seven Co., Ltd. (South Korea)
- Beurer GmbH (Germany)
- Mylan N.V. (USA)
- Boehringer Ingelheim International GmbH (Germany)
- PMS4PMS, LLC
- Sanofi (France)
- Nobelpharma Co., Ltd.
- ObsEva (Switzerland)
- Myovant Sciences Ltd. (Switzerland)
- AbbVie Inc. (USA)
- BioElectronics Corporation (USA)
- LIVIA
- Alvogen (USA)
- Cumberland Pharmaceuticals Inc. (USA)
- Lupin Pharmaceuticals, Inc. (USA)
- Janssen Pharmaceuticals, Inc. (USA)
- Sun Pharmaceutical Industries Ltd. (India)
Latest Developments in European Menstrual Cramps Treatment Market
- In March 2025, Samphire Neuroscience (London, UK), a pioneer in neurotechnology, officially launched Nettle, its CE-certified brain device designed to alleviate both mental and physical symptoms associated with menstruation. This initiative underscores the company's dedication to delivering innovative, non-pharmacological pain relief solutions tailored to the growing European demand for alternative and technology-driven menstrual health management. By leveraging its expertise in transcranial direct current stimulation (tDCS), Samphire Neuroscience is not only addressing discomfort but also reinforcing its position in the rapidly expanding femtech and digital therapeutics market.
- In 2024, Bayer AG (Leverkusen, Germany), a European leader in pharmaceuticals, strategically continued its focus on advancing treatments for endometriosis-associated pelvic pain, a significant cause of secondary dysmenorrhea in Europe. This ongoing commitment, exemplified by the sustained research and commercialization of products like Visanne, underscores the company's dedication to delivering effective medical solutions tailored to complex gynecological pain conditions. By leveraging its extensive R&D capabilities and established pharmaceutical expertise, Bayer AG is not only addressing chronic pain but also reinforcing its dominant position in the rapidly evolving women's health sector.
- In 2024, the European menstrual cramps treatment market strategically continued its focus on advancing non-hormonal and natural therapies, driven by strong consumer preference for ginger, turmeric, magnesium, and omega‑3 supplements—and the rising popularity of herbal patches and heat therapy devices
- In 2025, the European menstrual cramps treatment market strategically continued its focus on pioneering IoT-integrated wearable solutions, such as smart heat-patch underwear and Bluetooth-enabled heat pads designed to deliver targeted relief during menstruation—boosting adoption of portable, connected pain-management devices
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE MENSTRUAL CRAMPS TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PIPELINE ANALYSIS
4.1 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, PIPELINE ANALYSIS
5 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: REGULATIONS
6 PREMIUM INSIGHTS
6.1 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: ADOPTION RATE
6.1.1 DRIVERS AND BARRIERS FOR THE ADOPTIONS
6.2 MARKETING EXPENSES
6.3 PAYERS:
6.4 PHARMACIES COLD/HOT PADS MARKET SHARE:
7 EPIDEMIOLOGY
8 COVID-19 IMPACT ON EUROPE MENSTRUAL CRAMPS TREATMENT MARKET
8.1 PRICE IMPACT
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC INITIATIVES BY MARKET PLAYERS DURING COVID-19
8.5 CONCLUSION
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 GROWING PREVALENCE OF DYSMENORRHEA
9.1.2 RISING TECHNOLOGICAL ADVANCEMENTS
9.1.3 INCREASING RESEARCH AND DEVELOPMENT FOR DEVELOPING INNOVATIVE DRUGS AND THERAPIES
9.1.4 GOVERNMENT INITIATIVES WITH RESPECT TO WOMEN HEALTHCARE
9.1.5 INCREASING NUMBER OF TREATMENT OPTIONS
9.2 RESTRAINTS
9.2.1 PRODUCT RECALLS
9.2.2 LACK OF AWARENESS ABOUT REPRODUCTIVE HEALTH IN WOMEN
9.2.3 HIGH COST OF ENDOMETRIAL ABLATION AND HYSTERECTOMY
9.3 OPPORTUNITIES
9.3.1 RISE IN AWARENESS ABOUT DYSMENORRHEA
9.3.2 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS
9.3.3 RISING DISPOSABLE INCOME
9.4 CHALLENGES
9.4.1 TRADITIONAL FAMILY VALUE LEADING TO NO TREATMENT
9.4.2 SIDE EFFECTS AND COMPLICATIONS ASSOCIATED WITH LONG TERM TREATMENT
9.4.3 EFFECTIVENESS OF COMPLEMENTARY AND ALTERNATIVE THERAPIES
10 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE
10.1 OVERVIEW
10.2 PRIMARY DYSMENORRHEA
10.3 SECONDARY DYSMENORRHEA
11 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE
11.1 OVERVIEW
11.2 MEDICATION
11.2.1 FIRST LINE TREATMENT
11.2.1.1 Nonhormonal Therapy
11.2.1.1.1 Nonsteroidal Anti-Inflammatory Drugs
11.2.1.1.1.1 Ibuprofen
11.2.1.1.1.2 Naproxen
11.2.1.1.1.3 Celecoxib
11.2.1.1.1.4 Mefenamic Acid
11.2.1.1.1.5 Meclofenamate
11.2.1.1.2 Acetaminophen
11.2.1.2 Hormonal Replacement Therapy y
11.2.1.2.1 Combined Oral Contraceptives (Monophasic or Multiphasic)
11.2.1.2.1.1 Norethindrone/Ethinyl Estradiol
11.2.1.2.1.2 Extended-Cycle Oral Contraceptives
11.2.1.2.2 Extended-Cycle Oral Contraceptives
11.2.1.2.2.1 Levonorgestrel/Ethinyl Estradiol
11.2.1.2.2.2 Others
11.2.1.2.3 Other
11.2.1.2.3.1 Etonogestrel/Ethinyl Estradiol
11.2.1.2.3.2 Etonogestrel Implant
11.2.1.2.3.3 Levonorgestrel-Releasing Intrauterine System
11.2.1.2.3.4 Medroxyprogesterone Shot
11.2.1.3 Diuretic
11.2.1.3.1 Spironolactone
11.2.1.3.2 Ammonium Chloride
11.2.1.4 Antidepressants
11.2.2 SECOND LINE TREATMENT
11.2.2.1 Empiric GNRH Analogue or Antagonist Therapy
11.2.2.2 Ammonium Chloride
11.3 THERAPY
11.3.1 HEAT THERAPY
11.3.1.1 Patch
11.3.1.2 Wrap
11.3.1.3 Ceramic Belt Emitting Far-Infrared Radiation (FIR)
11.3.2 BEHAVIORAL COUNSELING
11.3.2.1 Desensitization-Based Procedures
11.3.2.2 Coping Strategies
11.3.2.3 Imagery
11.3.2.4 Hypnotherapy
11.3.2.5 Others
11.3.3 DIET AND VITAMINS
11.3.3.1 Vitamin E
11.3.3.2 Vitamin B
11.3.3.3 Vitamin D
11.3.3.4 Others
11.4 SURGERY
11.4.1 ENDOMETRIAL ABLATION
11.4.2 HYSTERECTOMY
11.5 OTHERS
12 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION
12.1 OVERVIEW
12.2 OVER THE COUNTER
12.3 PRESCRIPTION
13 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 ORAL
13.2.1 TABLETS
13.2.2 PILLS
13.2.3 CAPSULE
13.2.4 OTHERS
13.3 PARENTERAL
13.3.1 INTRAVENOUS
13.3.2 SUBCUTANEOUS
13.3.3 OTHERS
13.4 IMPLANTS
13.5 OTHERS
14 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 SPECIALTY CENTERS
14.4 AMBULATORY SURGICAL CENTERS
14.5 OTHERS
15 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 PHARMACIES
15.2.1 HOSPITAL
15.2.2 RETAIL
15.3 DIRECT TENDER
15.4 RETAIL SALES
15.5 OTHERS
16 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY GEOGRAPHY
16.1 EUROPE
16.1.1 GERMANY
16.1.2 FRANCE
16.1.3 U.K.
16.1.4 ITALY
16.1.5 NETHERLANDS
16.1.6 SPAIN
16.1.7 RUSSIA
16.1.8 SWITZERLAND
16.1.9 TURKEY
16.1.10 AUSTRIA
16.1.11 NORWAY
16.1.12 BELGIUM
16.1.13 HUNGARY
16.1.14 LITHUANIA
16.1.15 IRELAND
16.1.16 POLAND
16.1.17 REST OF EUROPE
17 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: EUROPE
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 GLAXOSMITHKLINE PLC.
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENT
19.3 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANLYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENTS
19.4 ABBVIE INC.
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 MYLAN N. V. (A PART OF VIATRIS INC.).
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 PRODUCT PORTFOLIO
19.5.4 RECENT DEVELOPMENT
19.6 ALVOGEN
19.6.1 COMPANY SNAPSHOT
19.6.2 PRODUCT PORTFOLIO
19.6.3 RECENT DEVELOPMENT
19.7 BAYER AG
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENTS
19.8 BEURER GMBH
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENT
19.9 BIOELECTRONICS CORPORATION
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENT
19.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENT
19.11 COLOR SEVEN CO., LTD.
19.11.1 COMPANY SNAPSHOT
19.11.2 PRODUCT PORTFOLIO
19.11.3 RECENT DEVELOPMENTS
19.12 CUMBERLAND PHARMACEUTICALS INC.
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENTS
19.13 LIVIA
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENTS
19.14 LUPIN PHARMACEUTICALS, INC. (A SUBSIDIARY OF LUPIN)
19.14.1 COMPANY SNAPSHOT
19.14.2 REVENUE ANALYSIS
19.14.3 PRODUCT PORTFOLIO
19.14.4 RECENT DEVELOPMENTS
19.15 MYOVANT SCIENCES LTD.
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENT
19.16 NOBELPHARMA CO., LTD.
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENT
19.17 OBSEVA
19.17.1 COMPANY SNAPSHOT
19.17.2 PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENTS
19.18 PFIZER INC.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENTS
19.19 PMS4PMS, LLC
19.19.1 COMPANY SNAPSHOT
19.19.2 PRODUCT PORTFOLIO
19.19.3 RECENT DEVELOPMENT
19.2 SANOFI
19.20.1 COMPANY SNAPSHOT
19.20.2 REVENUE ANALYSIS
19.20.3 PRODUCT PORTFOLIO
19.20.4 RECENT DEVELOPMENT
19.21 SUN PHARMACEUTICAL INDUSTRIES LTD.
19.21.1 COMPANY SNAPSHOT
19.21.2 REVENUE ANALYSIS
19.21.3 PRODUCT PORTFOLIO
19.21.4 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS
List of Table
LIST OF TABLES
TABLE 1 MARKETING EXPENSES OF THE MARKET PLAYERS
TABLE 2 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 3 EUROPE PRIMARY DYSMENORRHEA IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 4 EUROPE SECONDARY DYSMENORRHEA IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 6 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)
TABLE 7 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)
TABLE 8 EUROPE MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 EUROPE MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 10 EUROPE FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 11 EUROPE NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 12 EUROPE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 13 EUROPE HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 14 EUROPE COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 15 EUROPE EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 16 EUROPE OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 17 EUROPE DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 18 EUROPE SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 19 EUROPE THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 EUROPE THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 21 EUROPE HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 22 EUROPE BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 23 EUROPE DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 24 EUROPE SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 EUROPE SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 26 EUROPE OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)
TABLE 28 EUROPE OVER THE COUNTER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 EUROPE PRESCRIPTION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 31 EUROPE ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 EUROPE ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 33 EUROPE PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 EUROPE PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 35 EUROPE IMPLANTS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 EUROPE OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2020-2028 (USD MILLION)
TABLE 38 EUROPE HOSPITALS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 EUROPE SPECIALTY CENTERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 EUROPE AMBULATORY SURGICAL CENTERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 EUROPE OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
TABLE 43 EUROPE PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 EUROPE PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 45 EUROPE DIRECT TENDER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 46 EUROPE RETAIL SALES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 47 EUROPE OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 48 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 49 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 50 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 51 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)
TABLE 52 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)
TABLE 53 EUROPE MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 54 EUROPE FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 55 EUROPE NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 56 EUROPE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 57 EUROPE HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 58 EUROPE COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 59 EUROPE EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 60 EUROPE OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 61 EUROPE DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 62 EUROPE SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 63 EUROPE THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 64 EUROPE HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 65 EUROPE BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 66 EUROPE DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 67 EUROPE SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 68 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)
TABLE 69 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 70 EUROPE ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 71 EUROPE PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 72 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 73 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 74 EUROPE PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 75 GERMANY MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 76 GERMANY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 77 GERMANY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)
TABLE 78 ERMANY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)
TABLE 79 GERMANY MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 80 GERMANY FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 81 GERMANY NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 82 GERMANY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 83 GERMANY HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 84 GERMANY COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 85 GERMANY EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 86 GERMANY OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 87 GERMANY DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 88 GERMANY SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 89 GERMANY THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 90 GERMANY HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 91 GERMANY BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 92 GERMANY DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 93 GERMANY SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 94 GERMANY MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)
TABLE 95 GERMANY MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 96 GERMANY ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 97 GERMANY PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 98 GERMANY MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 99 GERMANY MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 100 GERMANY PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 101 FRANCE MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 102 FRANCE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 103 FRANCE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)
TABLE 104 FRANCE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)
TABLE 105 FRANCE MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 106 FRANCE FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 107 FRANCE NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 108 FRANCE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 109 FRANCE HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 110 FRANCE COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 111 FRANCE EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 112 FRANCE OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 113 FRANCE DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 114 FRANCE SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 115 FRANCE THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 116 FRANCE HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 117 FRANCE BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 118 FRANCE DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 119 FRANCE SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 120 FRANCE MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)
TABLE 121 FRANCE MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 122 FRANCE ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 123 FRANCE PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 124 FRANCE MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 125 FRANCE MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 126 FRANCE PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 127 U.K. MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 128 U.K. MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 129 U.K. MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)
TABLE 130 U.K. MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)
TABLE 131 U.K. MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 132 U.K. FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 133 U.K. NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 134 U.K. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 135 U.K. HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 136 U.K. COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 137 U.K. EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 138 U.K. OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 139 U.K. DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 140 U.K. SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 141 U.K. THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 142 U.K. HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 143 U.K. BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 144 U.K. DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 145 U.K. SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 146 U.K. MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)
TABLE 147 U.K. MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 148 U.K. ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 149 U.K. PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 150 U.K. MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 151 U.K. MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 152 U.K. PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 153 ITALY MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 154 ITALY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 155 ITALY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)
TABLE 156 ITALY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)
TABLE 157 ITALY MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 158 ITALY FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 159 ITALY NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 160 ITALY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 161 ITALY HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 162 ITALY COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 163 ITALY EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 164 ITALY OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 165 ITALY DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 166 ITALY SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 167 ITALY THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 168 ITALY HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 169 ITALY BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 170 ITALY DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 171 ITALY SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 172 ITALY MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)
TABLE 173 ITALY MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 174 ITALY ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 175 ITALY PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 176 ITALY MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 177 ITALY MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 178 ITALY PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 179 NETHERLANDS MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 180 NETHERLANDS MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 181 NETHERLANDS MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)
TABLE 182 NETHERLANDS MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)
TABLE 183 NETHERLANDS MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 184 NETHERLANDS FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 185 NETHERLANDS NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 186 NETHERLANDS NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 187 NETHERLANDS HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 188 NETHERLANDS COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 189 NETHERLANDS EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 190 NETHERLANDS OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 191 NETHERLANDS DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 192 NETHERLANDS SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 193 NETHERLANDS THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 194 NETHERLANDS HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 195 NETHERLANDS BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 196 NETHERLANDS DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 197 NETHERLANDS SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 198 NETHERLANDS MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)
TABLE 199 NETHERLANDS MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 200 NETHERLANDS ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 201 NETHERLANDS PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 202 NETHERLANDS MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 203 NETHERLANDS MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 204 NETHERLANDS PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 205 SPAIN MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 206 SPAIN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 207 SPAIN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)
TABLE 208 SPAIN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)
TABLE 209 SPAIN MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 210 SPAIN FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 211 SPAIN NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 212 SPAIN NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 213 SPAIN HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 214 SPAIN COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 215 SPAIN EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 216 SPAIN OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 217 SPAIN DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 218 SPAIN SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 219 SPAIN THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 220 SPAIN HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 221 SPAIN BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 222 SPAIN DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 223 SPAIN SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 224 SPAIN MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)
TABLE 225 SPAIN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 226 SPAIN ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 227 SPAIN PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 228 SPAIN MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 229 SPAIN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 230 SPAIN PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 231 RUSSIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 232 RUSSIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 233 RUSSIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)
TABLE 234 RUSSIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)
TABLE 235 RUSSIA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 236 RUSSIA FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 237 RUSSIA NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 238 RUSSIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 239 RUSSIA HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 240 RUSSIA COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 241 RUSSIA EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 242 RUSSIA OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 243 RUSSIA DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 244 RUSSIA SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 245 RUSSIA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 246 RUSSIA HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 247 RUSSIA BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 248 RUSSIA DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 249 RUSSIA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 250 RUSSIA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)
TABLE 251 RUSSIA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 252 RUSSIA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 253 RUSSIA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 254 RUSSIA MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 255 RUSSIA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 256 RUSSIA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 257 SWITZERLAND MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 258 SWITZERLAND MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 259 SWITZERLAND MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)
TABLE 260 SWITZERLAND MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)
TABLE 261 SWITZERLAND MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 262 SWITZERLAND FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 263 SWITZERLAND NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 264 SWITZERLAND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 265 SWITZERLAND HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 266 SWITZERLAND COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 267 SWITZERLAND EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 268 SWITZERLAND OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 269 SWITZERLAND DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 270 SWITZERLAND SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 271 SWITZERLAND THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 272 SWITZERLAND HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 273 SWITZERLAND BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 274 SWITZERLAND DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 275 SWITZERLAND SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 276 SWITZERLAND MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)
TABLE 277 SWITZERLAND MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 278 SWITZERLAND ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 279 SWITZERLAND PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 280 SWITZERLAND MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 281 SWITZERLAND MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 282 SWITZERLAND PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 283 TURKEY MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 284 TURKEY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 285 TURKEY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)
TABLE 286 TURKEY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)
TABLE 287 TURKEY MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 288 TURKEY FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 289 TURKEY NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 290 TURKEY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 291 TURKEY HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 292 TURKEY COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 293 TURKEY EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 294 TURKEY OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 295 TURKEY DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 296 TURKEY SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 297 TURKEY THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 298 TURKEY HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 299 TURKEY BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 300 TURKEY DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 301 TURKEY SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 302 TURKEY MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)
TABLE 303 TURKEY MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 304 TURKEY ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 305 TURKEY PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 306 TURKEY MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 307 TURKEY MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 308 TURKEY PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 309 AUSTRIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 310 AUSTRIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 311 AUSTRIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)
TABLE 312 AUSTRIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)
TABLE 313 AUSTRIA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 314 AUSTRIA FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 315 AUSTRIA NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 316 AUSTRIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 317 AUSTRIA HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 318 AUSTRIA COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 319 AUSTRIA EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 320 AUSTRIA OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 321 AUSTRIA DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 322 AUSTRIA SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 323 AUSTRIA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 324 AUSTRIA HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 325 AUSTRIA BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 326 AUSTRIA DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 327 AUSTRIA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 328 AUSTRIA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)
TABLE 329 AUSTRIA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 330 AUSTRIA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 331 AUSTRIA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 332 AUSTRIA MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 333 AUSTRIA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 334 AUSTRIA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 335 NORWAY MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 336 NORWAY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 337 NORWAY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)
TABLE 338 NORWAY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)
TABLE 339 NORWAY MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 340 NORWAY FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 341 NORWAY NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 342 NORWAY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 343 NORWAY HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 344 NORWAY COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 345 NORWAY EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 346 NORWAY OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 347 NORWAY DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 348 NORWAY SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 349 NORWAY THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 350 NORWAY HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 351 NORWAY BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 352 NORWAY DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 353 NORWAY SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 354 NORWAY MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)
TABLE 355 NORWAY MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 356 NORWAY ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 357 NORWAY PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 358 NORWAY MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 359 NORWAY MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 360 NORWAY PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 361 BELGIUM MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 362 BELGIUM MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 363 BELGIUM MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)
TABLE 364 BELGIUM MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)
TABLE 365 BELGIUM MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 366 BELGIUM FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 367 BELGIUM NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 368 BELGIUM NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 369 BELGIUM HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 370 BELGIUM COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 371 BELGIUM EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 372 BELGIUM OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 373 BELGIUM DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 374 BELGIUM SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 375 BELGIUM THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 376 BELGIUM HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 377 BELGIUM BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 378 BELGIUM DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 379 BELGIUM SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 380 BELGIUM MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)
TABLE 381 BELGIUM MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 382 BELGIUM ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 383 BELGIUM PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 384 BELGIUM MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 385 BELGIUM MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 386 BELGIUM PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 387 HUNGARY MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 388 HUNGARY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 389 HUNGARY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)
TABLE 390 HUNGARY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)
TABLE 391 HUNGARY MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 392 HUNGARY FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 393 HUNGARY NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 394 HUNGARY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 395 HUNGARY HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 396 HUNGARY COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 397 HUNGARY EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 398 HUNGARY OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 399 HUNGARY DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 400 HUNGARY SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 401 HUNGARY THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 402 HUNGARY HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 403 HUNGARY BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 404 HUNGARY DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 405 HUNGARY SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 406 HUNGARY MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)
TABLE 407 HUNGARY MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 408 HUNGARY ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 409 HUNGARY PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 410 HUNGARY MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 411 HUNGARY MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 412 HUNGARY PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 413 LITHUANIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 414 LITHUANIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 415 LITHUANIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)
TABLE 416 LITHUANIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)
TABLE 417 LITHUANIA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 418 LITHUANIA FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 419 LITHUANIA NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 420 LITHUANIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 421 LITHUANIA HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 422 LITHUANIA COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 423 LITHUANIA EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 424 LITHUANIA OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 425 LITHUANIA DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 426 LITHUANIA SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 427 LITHUANIA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 428 LITHUANIA HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 429 LITHUANIA BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 430 LITHUANIA DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 431 LITHUANIA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 432 LITHUANIA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)
TABLE 433 LITHUANIA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 434 LITHUANIA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 435 LITHUANIA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 436 LITHUANIA MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 437 LITHUANIA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 438 LITHUANIA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 439 IRELAND MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 440 IRELAND MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 441 IRELAND MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)
TABLE 442 IRELAND MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)
TABLE 443 IRELAND MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 444 IRELAND FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 445 IRELAND NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 446 IRELAND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 447 IRELAND HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 448 IRELAND COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 449 IRELAND EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 450 IRELAND OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 451 IRELAND DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 452 IRELAND SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 453 IRELAND THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 454 IRELAND HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 455 IRELAND BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 456 IRELAND DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 457 IRELAND SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 458 IRELAND MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)
TABLE 459 IRELAND MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 460 IRELAND ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 461 IRELAND PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 462 IRELAND MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 463 IRELAND MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 464 IRELAND PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 465 POLAND MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 466 POLAND MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 467 POLAND MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)
TABLE 468 POLAND MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)
TABLE 469 POLAND MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 470 POLAND FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 471 POLAND NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 472 POLAND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 473 POLAND HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 474 POLAND COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 475 POLAND EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 476 POLAND OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 477 POLAND DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 478 POLAND SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 479 POLAND THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 480 POLAND HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 481 POLAND BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 482 POLAND DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 483 POLAND SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 484 POLAND MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)
TABLE 485 POLAND MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 486 POLAND ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 487 POLAND PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 488 POLAND MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 489 POLAND MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 490 POLAND PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 491 REST OF EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
List of Figure
LIST OF FIGURES
FIGURE 1 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: SEGMENTATION
FIGURE 2 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: SEGMENTATION
FIGURE 10 INCREASING PREVALENCE OF DYSMENORRHEA IS EXPECTED TO DRIVE THE EUROPE MENSTRUAL CRAMPS TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 11 PRIMARY DYSMENORRHEA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE MENSTRUAL CRAMPS TREATMENT MARKET IN 2021 & 2028
FIGURE 12 PHARMACIES COLD/HOT PADS MARKET SHARE: 2020 (%)
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE MENSTRUAL CRAMPS TREATMENT MARKET
FIGURE 14 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, 2020
FIGURE 15 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, 2020-2028 (USD MILLION)
FIGURE 16 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 17 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 18 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, 2020
FIGURE 19 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, 2020-2028 (USD MILLION)
FIGURE 20 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2021-2028)
FIGURE 21 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 22 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION, 2020
FIGURE 23 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION 2020-2028 (USD MILLION)
FIGURE 24 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION, CAGR (2021-2028)
FIGURE 25 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION, LIFELINE CURVE
FIGURE 26 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 27 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)
FIGURE 28 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 29 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 30 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, 2020
FIGURE 31 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 32 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, CAGR (2021-2028)
FIGURE 33 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 34 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 35 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 36 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 37 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: SNAPSHOT (2020)
FIGURE 39 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY COUNTRY (2020)
FIGURE 40 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY COUNTRY (2021 & 2028)
FIGURE 41 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY COUNTRY (2020 & 2028)
FIGURE 42 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE (2021-2028)
FIGURE 43 EUROPE MENSTRUAL CRAMPS TREATMENT MARKET: COMPANY SHARE 2020 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
